Inhibitors of HER2/neu (erbB-2) signal transduction

Seminars in Oncology

Volumn 28, Issue 6 SUPPL. 18, 2001, Pages 30-35

  Arteaga, Carlos L ^a   Chinratanalab, Wichai ^a,b,c   Carter, Mary Beth ^a,b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6 (METHYLAMINO)PYRIDO[3,4 D]PYRIMIDINE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HER2; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; SU 5259; TRASTUZUMAB; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CELL CULTURE; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; GENE OVEREXPRESSION; HUMAN; IC 50; MALIGNANT TRANSFORMATION; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

EID: 0035687013     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0093-7754(01)90106-X     Document Type: Article

References (32)

1. Specificity within the EGF family/ErbB receptor family signaling network
2. The ErbB signaling network in embryogenesis and oncogenesis: Signal diversification through combinatorial ligand-receptor interactions
3. The ErbB-2/HER-2 oncogenic receptor of adenocarcinomas: From orphanhood to multiple stromal ligands
4. ErbB receptors and EGF-like ligands: Cell lineage determination and oncogenesis through combinatorial signaling
5. Suppression and promotion of tumor growth by monoclonal antibodies to erbB-2 differentially correlate with cellular uptake
6. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER-2 block crosstalk with growth factor receptors
7. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells
8. Phase II study of weekly intravenous recombinant humanized anti-p185HER-2 monoclonal antibody in patients with HER-2/neu-overexpressing metastatic breast cancer
9. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
10. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
11. The humanized anti-HER-2 rhuMAB HER-2 mediates antibody-dependent cell-mediated cytotoxicity via FcγR III
12. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
13. Tyrosine kinases in disease: Overview of kinase inhibitors as therapeutic agents and current drugs in clinical trials
14. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB-2, by a new class of tyrosine kinase inhibitor
15. Biochemical and antiproliferative properties of 4,[ar(alk)yl-amino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor
16. Unliganded epidermal growth factor receptor dimerization induced by direct interaction of quinazolines with the ATP binding site
17. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase
18. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner
19. Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase
20. Reversible G 1 arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires upregulation of p27KIP1 independent of MAP kinase activity
21. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts
22. Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones, and interactions with neu
23. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation of human mammary carcinoma cells
24. Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185 neu/erbB-2 in a subset of human breast tumors overexpressing this receptor
25. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: Implications for breast cancer
26. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
27. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling
28. Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation
29. Augmentation of a humanized anti-HER-2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225
30. Tyrosine kinase inhibition: An approach to drug development
31. ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development
32. Phase 1 study of oral ZD1839 (lressa), a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK): Evidence of good tolerability and activity